Announcements
- New data with daridorexant to be presented at SLEEP 2024
- Data from the PRECISION study of aprocitentan to be presented at the European Society of Hypertension Annual Meeting 2024
- Idorsia issues invitation to the 2024 Annual General Meeting of Shareholders
- Idorsia announces changes to Idorsia Executive Committee and Board of Directors
- Idorsia announces financial results for the first quarter 2024 – advancing the company with renewed vigor
- Idorsia announces financial results for the full year of 2023 – Adapting the company to create sustainable value
- Invitation to Idorsia's Full Year 2023 and Q1 2024 Financial Reporting webcast and conference call
- Bondholders approve amended terms of the 2024 convertible bonds
- Idorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bond
- JERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertension
More ▼
Key statistics
Short selling activityProvided by S&P Global Market Intelligence
Open | 18.13 |
---|---|
High | 19.57 |
Low | 18.13 |
Bid | 19.45 |
Offer | 20.74 |
Previous close | 19.54 |
Average volume | -- |
---|---|
Shares outstanding | 188.97m |
Free float | 111.81m |
P/E (TTM) | -- |
Market cap | 447.10m CHF |
EPS (TTM) | -0.3534 CHF |
Data delayed at least 15 minutes, as of Jun 28 2019.
More ▼